A new target for simultaneous inhibition of hem- and lymphangiogenesis

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 6, 2013, Pages 4286-

  Ambati, Balamurali ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN LIKE PROTEIN 2; ANGIOPOIETIN RECEPTOR; GROWTH FACTOR; INTERLEUKIN 1BETA; TIE 1 RECEPTOR; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VOLOCIXIMAB;

ANGIOGENESIS; ARTICLE; CORNEA TRANSPLANTATION; DIABETIC RETINOPATHY; GRAFT REJECTION; HEMANGIOGENESIS; HUMAN; LYMPHANGIOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA DEGENERATION;

ANGIOPOIETINS; ANIMALS; KERATITIS; LYMPHANGIOGENESIS; MALE; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84879569541     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12449     Document Type: Article

References (1)

1. Toyono T, Usui T, Yokoo S, et al. Angiopoietin-like protein 2 is a potent hemangiogenic and lymphangiogenic factor in corneal inflammation. Invest Ophthalmol Vis Sci. 2013;54:4278-4285.